Carisma Therapeutics (CARM) - 2023 Q4 - Annual Report

immunology programs are wholly owned. Additionally, under a collaboration agreement with Moderna, we are developing in vivo CAR-M therapies utilizing Moderna's mRNA/LNP, technology. Our current pipeline is summarized below: Our Strategy Table of Contents 4Q 2024: Initial data (Next-Gan CAR2) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________ ____________________________________________________________ (Mark O ...